Neurostimulation Devices
Aug 08, 2024
MIMEDX Launches HELIOGENTM Fibrillar Collagen Matrix; DocGo Launches Mobile X-ray Program; Labcrop’s FDA De Novo Marketing Authorization; Inspire Medical Systems Receives FDA Approval; Alcyone Therapeutics Announces Continued Enrollment Approval from the FDA; Lunit’s AI for Tuberculosis Detection
MIMEDX Announced the Launch of HELIOGENTM Fibrillar Collagen Matrix On July 31, 2024, MiMedx Group, Inc. launched HELIOGEN™ Fibrillar Collagen Matrix, a particulate xenograft product designed to treat complex wounds, especially in surgical environments. HELIOGEN is a shelf-stable product that contains Type...
Read More...
Jul 11, 2024
Cordis FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device; Forma Medical’s Optimal Plating System FDA Approval; Virpax’s Swine Model Pilot Study Positive Results; SetPoint Medical Positive Topline Results from Pioneering RESET-RA Study; Signature Orthopaedics Partnered with THINK Surgical; Nusano and PharmaLogic Formed Strategic Supply Agreement
Cordis Secured FDA Approval for MYNX CONTROL VENOUS Vascular Closure Device, Expanding Proven MYNX Technology to Mid-Bore Venous Puncture Sites On July 9, 2024, Cordis, a leading company in cardiovascular and endovascular technology, received FDA approval for its MYNX CONTROL™ VENOUS Vascular Closure Device. Thi...
Read More...
Apr 04, 2024
C2Dx’s Shaw Scalpel System; Texas Original’s RSO Gummies; Abbott’s Whole Blood Rapid Test FDA Clearance; Medtronic’s TAVR Device FDA Clearance; Nexalin’s Device Improved Symptoms; CYduct Diagnostics’ Positive Study Results
C2Dx Launched Next Generation Shaw Scalpel System On March 26, 2024, C2Dx, a privately-owned medical device company, announced the launch of its Next Generation Shaw Scalpel System. The Shaw Scalpel System has obtained 510(k) clearance from the FDA for the upgraded controller of its advanced surgical techn...
Read More...
Jan 18, 2024
Epredia Announced the US Launch of SlideMate Laser; Olympus, Canon Medical Announced Partnership; FDA Cleared Painful Diabetic Neuropathy Neurostim Therapy from Neuralace; FDA Clearance to Bloomlife’s Bloomlife MFM-Pro; BrainsWay Initiated New Studies of Non-Invasive Neurostim; Gore Enrolled First Patients in Expandable Stent Graft Trial
Epredia Announced the US Launch of SlideMate™ Laser, Providing State-of-the-Art Precision Slide Printing for Pathology Laboratories On January 11, 2024, Epredia, a global leader in precision cancer diagnostics, announced that the company launched US sales of SlideMate™ Laser, the newest addition to the company’s...
Read More...
Feb 02, 2023
Alma Announced the Launch of Alma Duo; Phillips-Medisize Launched a Pen Injector Platform; FDA Approved Abbott’s Spinal Cord Stimulation; Axonics Received FDA Approval for Rechargeable Sacral Neuromodulation; SELUTION SLR Coronary Sirolimus DEB Study Enrolls First Patient; AtriCure LeAAPS Clinical Trial
Alma announced the Launch of Alma Duo- an Advanced Solution for Sexual Wellness On January 26, 2023, Alma, the core subsidiary of Sisram Medical and one of the leaders of energy-based medical and aesthetics solutions, launched its new sexual wellness product, Alma Duo. Alma Duo is a cutting-edge, safe, non-in...
Read More...
Nov 24, 2022
Mainstay Medical’s ReActiv8-C Study; Swing Therapeutics Announced Results from Studies of Stanza; FDA Approves Empatica’s Health Monitoring Platform; FDA Clearance to Persona OsseoTi Keel Tibia System; ClariPi Joins Siemens Healthineers Digital Marketplace; Sony Launches Cloud-based Solution for Flow Cytometry Data Analysis
Mainstay Medical Published Post-Market Clinical Trial Data from Ongoing ReActiv8®-C Study On November 22, 2022, Mainstay Medical, a medical devices company, announced that the data from the ReActiv8®-C study, a single-centre, real-world study with a one-year clinical follow-up of selected patients, is publ...
Read More...
Jul 27, 2022
How are Neurostimulation Devices Playing a Vital Role in the Treatment of Chronic Pain?
Around 50 million people in the United States live with—and suffer from—chronic pain. The prevalence of chronic pain has grown significantly over the past few decades due to lifestyle changes, traumatic injury, a rise in critical surgeries, and growth in the overweight or obese population, among serval other underl...
Read More...
Jul 21, 2022
FDA Approval to Centinel’s Total Disc Replacement Devices; FDA clears DyAnsys’ Neurostimulator; Orthox to Commence FFLEX Study; Cordis Started Enrolment for RADIANCY Clinical Study; Orthofix & LimaCorporate Announce Partnership; Medtronic to Partner With AWS
Orthox Obtains MHRA Approval to Commence FFLEX Study On July 14, 2022, Orthodox Ltd, a clinical-stage company created medical implants to treat orthopedic problems including damaged knee articular cartilage. It was founded in 2008 by life scientist, Dr. Nick Skaer, and knee surgeon, Professor Oliver Kessle...
Read More...
Mar 03, 2022
Noninvasix’s LIVOx™ Central Venous Oxygenation Monitor; LivaNova’s aura6000 System; Oxford BioDynamics’s EpiSwitch® CiRT; Masimo’s SedLine® Brain Function Monitoring and the SedLine Pediatric EEG Sensor; Medtronic’s NuVent™ Eustachian Tube Dilation Balloon; Conformis’s published data for Bilateral Knee Implant Study
Noninvasix Granted the US FDA Breakthrough Device Designation for Non-Invasive Monitoring Technology for Sepsis On February 23, 2022, Noninvasix, Inc. received the US FDA breakthrough device designation for its LIVOx™ Central Venous Oxygenation Monitor. It is a non-invasive device and provides real-time, ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
